Compare · BON vs DFTX
BON vs DFTX
Side-by-side comparison of Bon Natural Life Limited (BON) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BON and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 501.2x BON ($9.2M).
- Over the past year, BON is down 43.4% and DFTX is up 135.6% - DFTX leads by 179.0 points.
- DFTX has been more active in the news (11 items in the past 4 weeks vs 1 for BON).
- DFTX has more recent analyst coverage (8 ratings vs 0 for BON).
PerformanceBON-43.40%DFTX+135.57%
2025-10-17+0.00%2026-10-16
- Company
- Bon Natural Life Limited
- Definium Therapeutics Inc.
- Price
- $1.11-3.88%
- $32.12-6.23%
- Market cap
- $9.2M
- $4.60B
- 1M return
- +1.36%
- -17.01%
- 1Y return
- -43.40%
- +135.57%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 1
- 11
- Recent ratings
- 0
- 8
Latest BON
- SEC Form 6-K filed by Bon Natural Life Limited
- SEC Form 3 filed by new insider Zhixiang Gao
- SEC Form 3 filed by new insider Chen Jing Veronica
- SEC Form 3 filed by new insider Hu Yongwei
- SEC Form 3 filed by new insider Xue Yingchun
- SEC Form 3 filed by new insider Ma Xin
- SEC Form 3 filed by new insider Wenjuan Chen
- SEC Form 3 filed by new insider Liu Jing
- SEC Form 3 filed by new insider Gao Jianjun
- BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.